Loading...
•
Dec 31, 2022
Immunic Q4 2022 Earnings Report
Immunic reported financial results for the year ended December 31, 2022 and provided a corporate update.
Key Takeaways
Immunic reported its year end 2022 financial results, highlighting the progress of vidofludimus calcium for multiple sclerosis treatment and upcoming data readouts from clinical trials. The company's cash reserves are expected to fund operations into the fourth quarter of 2024.
Advanced vidofludimus calcium for multiple sclerosis (MS) treatment.
Anticipate interim analysis of phase 2 CALLIPER trial in progressive MS in the second half of 2023.
Expect data from the interim analysis of the phase 3 ENSURE program late next year.
IMU-856 shows potential as a first-in-class oral celiac disease therapy.
Forward Guidance
Immunic anticipates several clinical milestones in the near future, including data readouts from ongoing trials for vidofludimus calcium and IMU-856.
Positive Outlook
- Interim analysis of phase 2 CALLIPER trial of Vidofludimus Calcium in Progressive Multiple Sclerosis expected in the second half of 2023
- Initial Results From Ongoing Part C of Phase 1 Clinical Trial of IMU-856 in Celiac Disease Expected Mid-2023
- The CALLIPER trial is designed to corroborate the neuroprotective potential of vidofludimus calcium
- Design of the ENSURE program gives Immunic a straightforward path toward potential regulatory approval in relapsing MS
- Vidofludimus calcium has the potential to be a unique treatment option targeted to the biology of MS, differentiated by its combined anti-inflammatory, antiviral and neuroprotective effects
Challenges Ahead
- The COVID-19 pandemic
- Increasing inflation
- Impacts of the Ukraine – Russia conflict on planned and ongoing clinical trials
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...